| . | Denominator of QI . | Numerator of QI . |
|---|---|---|
| QI 1-1 | Female patients with SLE planning for pregnancy | Patients who consulted an obstetrician |
| QI 1-2 | Female patients of childbearing age with SLE | Patients explaining the need for a planned pregnancy |
| QI 1-3 | Female patients of childbearing age with SLE who are aPL negative, have stable or low disease activity, have no desire to have a baby, and wish to use contraception | Patients proposed effective contraceptive methods (e.g. hormonal contraceptives or intrauterine devices) |
| QI 1-4 | Female patients of childbearing age with SLE of moderate-to-severe disease activity, including nephritis | Patients proposed to use progestin-only contraceptive pills or intrauterine device for contraception |
| QI 1-5 | Male patients with SLE who have not started treatment with gonadotoxic drugs and who plan to become pregnant | Patients who proposed cryopreservation of sperm |
| QI 1-6 | Female patients of childbearing age with SLE who are on fertility medications, have stable disease activity, aPL negative, and desire to have a baby | Patient proposed assisted reproductive treatment if necessary |
| QI 1-7 | Female patients with SLE who have stable disease activity and undergo ovarian stimulation | Patients continued on necessary and tolerable immunosuppressive medications |
| QI 1-8 | Obstetric and/or thrombotic APS female patients | Patients who avoided hormone replacement therapy in assisted reproductive medicine |
| QI 1-9 | Female patients with SLE planning pregnancy | Patients in remission for at least 6 months prior to pregnancy |
| QI 1-10 | Female SLE patients with severe pulmonary hypertension* *Estimated systolic PAP >50 mmHg or symptomatic | Patients explained contraception |
| QI 1-11 | Female SLE patients with severe constrictive lung disease* *FVC <50% of predicted value | Patients explained contraception |
| QI 1-12 | Female patients with SLE with severe heart failure* *WHO Class IV including severe ventricular dysfunction with LVEF <30% and NYHA Class III–IV | Patients explained contraception |
| QI 1-13 | Female patients with SLE with severe renal failure* *Serum creatinine ≥ 2.8 mg/dl (500 mmol/l) | Patients explained contraception |
| QI 1-14 | Female patients with SLE who developed thrombosis within 6 months | Patients explained contraception |
| QI 1-15 | Female patients with SLE who had a flare-up of lupus nephritis | Patients explained contraception for 6 months after remission |
| QI 2-1 | Patients with SLE before and during the first trimester of pregnancy | Patients tested for anti-SS-A/Ro and anti-SS-B/La antibodies |
| QI 2-2 | Patients with SLE before pregnancy | Patients tested for aPL |
| QI 2-3 | Patients with SLE planning a pregnancy | Patients with complete blood count and biochemistry, renal function parameters (urinalysis including sediment, urine protein/creatinine ratio), C3, C4, and double-stranded anti-DNA antibodies tested at the stage of planned pregnancy |
| QI 2-4 | Pregnant patients with SLE with lupus nephritis in remission | Patients with serum creatinine and urine protein-creatinine ratios tested at least every 4 weeks |
| QI 2-5 | Pregnant patients with SLE with lupus nephritis | Patients who had blood pressure measurements and urinalysis every 4 weeks until 28 weeks’ gestation, every 2 weeks until 36 weeks, and then weekly thereafter until delivery |
| QI 2-6 | Pregnant patients with SLE positive for anti-SS-A/Ro and/or anti-SS-B/La antibodies | Patients tested for foetal echocardiography |
| QI 3-1 | Patients with SLE starting treatment with drugs that may affect gonadal function | Patients discussing pregnancy planning prior to drug initiation |
| QI 3-2 | Patient with SLE who discontinued teratogenic drugs prior to pregnancy | Patients who have been observed without medication or transitioned to a drug that can be used during pregnancy |
| QI 3-3 | Female patient with SLE planning pregnancy | Patients who discontinued MTX at least 1 month prior to pregnancy |
| QI 3-4 | Female patient with SLE planning pregnancy | Patients who discontinued MMF at least 6 weeks prior to pregnancy |
| QI 3-5 | Female patient with SLE planning pregnancy | Patients who discontinued CYC at least 3 months prior to pregnancy |
| QI 3-6 | Male patients with SLE who wish to become pregnant | Patients who avoided receiving CYC |
| QI 3-7 | Male patients with SLE who are using HCQ and AZP and wish to become pregnant | Patients who continued to use HCQ and AZP |
| QI 3-8 | Pregnant patients with SLE who have been inadvertently exposed to teratogenic agents | Patients referred immediately to a maternal foetal medicine specialist, a pregnancy pharmacotherapy specialist, or a genetics counsellor |
| QI 3-9 | Pregnant SLE patient with APS | Patients treated with low-dose aspirin and heparin |
| QI 3-10 | Pregnant SLE patient with APS | Patients who avoided using DOAC |
| QI 3-11 | Pregnant patients with SLE | Patients who avoided the use of MMF, MTX, and CYC |
| QI 3-12 | Pregnant patients with SLE using HCQ | Patients who continued on HCQ during pregnancy |
| QI 3-13 | Female patients with SLE who is positive for anti-SS-A/Ro antibodies and has a history of congenital heart block in a previous child | Patients using HCQ |
| QI 3-14 | Pregnant patients with SLE | Patients who avoided the use of NSAIDs in the third trimester of pregnancy |
| QI 3-15 | Pregnant patients with SLE | Patients who avoided using ARB |
| QI 3-16 | Pregnant patients with SLE on CyA and TAC | Patients monitored for blood pressure, renal function, and drug concentrations |
| QI 3-17 | Obstetric APS patients | Patients receiving prophylactic anticoagulation therapy during the first 6–12 weeks postpartum |
| QI 3-18 | Patients with SLE who are taking corticosteroids and who are breastfeeding | Patients who continued to breastfeed |
| QI 3-19 | Patients with SLE who are using HCQ, AZP, TAC, or rituximab and who are breastfeeding | Patients who continued to use HCQ, AZP, TAC, or rituximab |
| QI 3-20 | Patient with SLE who is breastfeeding | Patients who avoided using CYC and MMF |
| . | Denominator of QI . | Numerator of QI . |
|---|---|---|
| QI 1-1 | Female patients with SLE planning for pregnancy | Patients who consulted an obstetrician |
| QI 1-2 | Female patients of childbearing age with SLE | Patients explaining the need for a planned pregnancy |
| QI 1-3 | Female patients of childbearing age with SLE who are aPL negative, have stable or low disease activity, have no desire to have a baby, and wish to use contraception | Patients proposed effective contraceptive methods (e.g. hormonal contraceptives or intrauterine devices) |
| QI 1-4 | Female patients of childbearing age with SLE of moderate-to-severe disease activity, including nephritis | Patients proposed to use progestin-only contraceptive pills or intrauterine device for contraception |
| QI 1-5 | Male patients with SLE who have not started treatment with gonadotoxic drugs and who plan to become pregnant | Patients who proposed cryopreservation of sperm |
| QI 1-6 | Female patients of childbearing age with SLE who are on fertility medications, have stable disease activity, aPL negative, and desire to have a baby | Patient proposed assisted reproductive treatment if necessary |
| QI 1-7 | Female patients with SLE who have stable disease activity and undergo ovarian stimulation | Patients continued on necessary and tolerable immunosuppressive medications |
| QI 1-8 | Obstetric and/or thrombotic APS female patients | Patients who avoided hormone replacement therapy in assisted reproductive medicine |
| QI 1-9 | Female patients with SLE planning pregnancy | Patients in remission for at least 6 months prior to pregnancy |
| QI 1-10 | Female SLE patients with severe pulmonary hypertension* *Estimated systolic PAP >50 mmHg or symptomatic | Patients explained contraception |
| QI 1-11 | Female SLE patients with severe constrictive lung disease* *FVC <50% of predicted value | Patients explained contraception |
| QI 1-12 | Female patients with SLE with severe heart failure* *WHO Class IV including severe ventricular dysfunction with LVEF <30% and NYHA Class III–IV | Patients explained contraception |
| QI 1-13 | Female patients with SLE with severe renal failure* *Serum creatinine ≥ 2.8 mg/dl (500 mmol/l) | Patients explained contraception |
| QI 1-14 | Female patients with SLE who developed thrombosis within 6 months | Patients explained contraception |
| QI 1-15 | Female patients with SLE who had a flare-up of lupus nephritis | Patients explained contraception for 6 months after remission |
| QI 2-1 | Patients with SLE before and during the first trimester of pregnancy | Patients tested for anti-SS-A/Ro and anti-SS-B/La antibodies |
| QI 2-2 | Patients with SLE before pregnancy | Patients tested for aPL |
| QI 2-3 | Patients with SLE planning a pregnancy | Patients with complete blood count and biochemistry, renal function parameters (urinalysis including sediment, urine protein/creatinine ratio), C3, C4, and double-stranded anti-DNA antibodies tested at the stage of planned pregnancy |
| QI 2-4 | Pregnant patients with SLE with lupus nephritis in remission | Patients with serum creatinine and urine protein-creatinine ratios tested at least every 4 weeks |
| QI 2-5 | Pregnant patients with SLE with lupus nephritis | Patients who had blood pressure measurements and urinalysis every 4 weeks until 28 weeks’ gestation, every 2 weeks until 36 weeks, and then weekly thereafter until delivery |
| QI 2-6 | Pregnant patients with SLE positive for anti-SS-A/Ro and/or anti-SS-B/La antibodies | Patients tested for foetal echocardiography |
| QI 3-1 | Patients with SLE starting treatment with drugs that may affect gonadal function | Patients discussing pregnancy planning prior to drug initiation |
| QI 3-2 | Patient with SLE who discontinued teratogenic drugs prior to pregnancy | Patients who have been observed without medication or transitioned to a drug that can be used during pregnancy |
| QI 3-3 | Female patient with SLE planning pregnancy | Patients who discontinued MTX at least 1 month prior to pregnancy |
| QI 3-4 | Female patient with SLE planning pregnancy | Patients who discontinued MMF at least 6 weeks prior to pregnancy |
| QI 3-5 | Female patient with SLE planning pregnancy | Patients who discontinued CYC at least 3 months prior to pregnancy |
| QI 3-6 | Male patients with SLE who wish to become pregnant | Patients who avoided receiving CYC |
| QI 3-7 | Male patients with SLE who are using HCQ and AZP and wish to become pregnant | Patients who continued to use HCQ and AZP |
| QI 3-8 | Pregnant patients with SLE who have been inadvertently exposed to teratogenic agents | Patients referred immediately to a maternal foetal medicine specialist, a pregnancy pharmacotherapy specialist, or a genetics counsellor |
| QI 3-9 | Pregnant SLE patient with APS | Patients treated with low-dose aspirin and heparin |
| QI 3-10 | Pregnant SLE patient with APS | Patients who avoided using DOAC |
| QI 3-11 | Pregnant patients with SLE | Patients who avoided the use of MMF, MTX, and CYC |
| QI 3-12 | Pregnant patients with SLE using HCQ | Patients who continued on HCQ during pregnancy |
| QI 3-13 | Female patients with SLE who is positive for anti-SS-A/Ro antibodies and has a history of congenital heart block in a previous child | Patients using HCQ |
| QI 3-14 | Pregnant patients with SLE | Patients who avoided the use of NSAIDs in the third trimester of pregnancy |
| QI 3-15 | Pregnant patients with SLE | Patients who avoided using ARB |
| QI 3-16 | Pregnant patients with SLE on CyA and TAC | Patients monitored for blood pressure, renal function, and drug concentrations |
| QI 3-17 | Obstetric APS patients | Patients receiving prophylactic anticoagulation therapy during the first 6–12 weeks postpartum |
| QI 3-18 | Patients with SLE who are taking corticosteroids and who are breastfeeding | Patients who continued to breastfeed |
| QI 3-19 | Patients with SLE who are using HCQ, AZP, TAC, or rituximab and who are breastfeeding | Patients who continued to use HCQ, AZP, TAC, or rituximab |
| QI 3-20 | Patient with SLE who is breastfeeding | Patients who avoided using CYC and MMF |
Abbreviations: PAP, pulmonary arterial pressure; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; MTX, methotrexate; MMF, mycophenolate mofetil; CYC, cyclophosphamide; HCQ, hydroxychloroquine; AZP, azathioprine; DOAC, direct oral anticoagulant; NSAIDs, non-steroidal anti-inflammatory drugs; ARB, angiotensin-II receptor blocker; CyA, cyclosporin A; TAC, tacrolimus; WHO, World Health Organization.
| . | Denominator of QI . | Numerator of QI . |
|---|---|---|
| QI 1-1 | Female patients with SLE planning for pregnancy | Patients who consulted an obstetrician |
| QI 1-2 | Female patients of childbearing age with SLE | Patients explaining the need for a planned pregnancy |
| QI 1-3 | Female patients of childbearing age with SLE who are aPL negative, have stable or low disease activity, have no desire to have a baby, and wish to use contraception | Patients proposed effective contraceptive methods (e.g. hormonal contraceptives or intrauterine devices) |
| QI 1-4 | Female patients of childbearing age with SLE of moderate-to-severe disease activity, including nephritis | Patients proposed to use progestin-only contraceptive pills or intrauterine device for contraception |
| QI 1-5 | Male patients with SLE who have not started treatment with gonadotoxic drugs and who plan to become pregnant | Patients who proposed cryopreservation of sperm |
| QI 1-6 | Female patients of childbearing age with SLE who are on fertility medications, have stable disease activity, aPL negative, and desire to have a baby | Patient proposed assisted reproductive treatment if necessary |
| QI 1-7 | Female patients with SLE who have stable disease activity and undergo ovarian stimulation | Patients continued on necessary and tolerable immunosuppressive medications |
| QI 1-8 | Obstetric and/or thrombotic APS female patients | Patients who avoided hormone replacement therapy in assisted reproductive medicine |
| QI 1-9 | Female patients with SLE planning pregnancy | Patients in remission for at least 6 months prior to pregnancy |
| QI 1-10 | Female SLE patients with severe pulmonary hypertension* *Estimated systolic PAP >50 mmHg or symptomatic | Patients explained contraception |
| QI 1-11 | Female SLE patients with severe constrictive lung disease* *FVC <50% of predicted value | Patients explained contraception |
| QI 1-12 | Female patients with SLE with severe heart failure* *WHO Class IV including severe ventricular dysfunction with LVEF <30% and NYHA Class III–IV | Patients explained contraception |
| QI 1-13 | Female patients with SLE with severe renal failure* *Serum creatinine ≥ 2.8 mg/dl (500 mmol/l) | Patients explained contraception |
| QI 1-14 | Female patients with SLE who developed thrombosis within 6 months | Patients explained contraception |
| QI 1-15 | Female patients with SLE who had a flare-up of lupus nephritis | Patients explained contraception for 6 months after remission |
| QI 2-1 | Patients with SLE before and during the first trimester of pregnancy | Patients tested for anti-SS-A/Ro and anti-SS-B/La antibodies |
| QI 2-2 | Patients with SLE before pregnancy | Patients tested for aPL |
| QI 2-3 | Patients with SLE planning a pregnancy | Patients with complete blood count and biochemistry, renal function parameters (urinalysis including sediment, urine protein/creatinine ratio), C3, C4, and double-stranded anti-DNA antibodies tested at the stage of planned pregnancy |
| QI 2-4 | Pregnant patients with SLE with lupus nephritis in remission | Patients with serum creatinine and urine protein-creatinine ratios tested at least every 4 weeks |
| QI 2-5 | Pregnant patients with SLE with lupus nephritis | Patients who had blood pressure measurements and urinalysis every 4 weeks until 28 weeks’ gestation, every 2 weeks until 36 weeks, and then weekly thereafter until delivery |
| QI 2-6 | Pregnant patients with SLE positive for anti-SS-A/Ro and/or anti-SS-B/La antibodies | Patients tested for foetal echocardiography |
| QI 3-1 | Patients with SLE starting treatment with drugs that may affect gonadal function | Patients discussing pregnancy planning prior to drug initiation |
| QI 3-2 | Patient with SLE who discontinued teratogenic drugs prior to pregnancy | Patients who have been observed without medication or transitioned to a drug that can be used during pregnancy |
| QI 3-3 | Female patient with SLE planning pregnancy | Patients who discontinued MTX at least 1 month prior to pregnancy |
| QI 3-4 | Female patient with SLE planning pregnancy | Patients who discontinued MMF at least 6 weeks prior to pregnancy |
| QI 3-5 | Female patient with SLE planning pregnancy | Patients who discontinued CYC at least 3 months prior to pregnancy |
| QI 3-6 | Male patients with SLE who wish to become pregnant | Patients who avoided receiving CYC |
| QI 3-7 | Male patients with SLE who are using HCQ and AZP and wish to become pregnant | Patients who continued to use HCQ and AZP |
| QI 3-8 | Pregnant patients with SLE who have been inadvertently exposed to teratogenic agents | Patients referred immediately to a maternal foetal medicine specialist, a pregnancy pharmacotherapy specialist, or a genetics counsellor |
| QI 3-9 | Pregnant SLE patient with APS | Patients treated with low-dose aspirin and heparin |
| QI 3-10 | Pregnant SLE patient with APS | Patients who avoided using DOAC |
| QI 3-11 | Pregnant patients with SLE | Patients who avoided the use of MMF, MTX, and CYC |
| QI 3-12 | Pregnant patients with SLE using HCQ | Patients who continued on HCQ during pregnancy |
| QI 3-13 | Female patients with SLE who is positive for anti-SS-A/Ro antibodies and has a history of congenital heart block in a previous child | Patients using HCQ |
| QI 3-14 | Pregnant patients with SLE | Patients who avoided the use of NSAIDs in the third trimester of pregnancy |
| QI 3-15 | Pregnant patients with SLE | Patients who avoided using ARB |
| QI 3-16 | Pregnant patients with SLE on CyA and TAC | Patients monitored for blood pressure, renal function, and drug concentrations |
| QI 3-17 | Obstetric APS patients | Patients receiving prophylactic anticoagulation therapy during the first 6–12 weeks postpartum |
| QI 3-18 | Patients with SLE who are taking corticosteroids and who are breastfeeding | Patients who continued to breastfeed |
| QI 3-19 | Patients with SLE who are using HCQ, AZP, TAC, or rituximab and who are breastfeeding | Patients who continued to use HCQ, AZP, TAC, or rituximab |
| QI 3-20 | Patient with SLE who is breastfeeding | Patients who avoided using CYC and MMF |
| . | Denominator of QI . | Numerator of QI . |
|---|---|---|
| QI 1-1 | Female patients with SLE planning for pregnancy | Patients who consulted an obstetrician |
| QI 1-2 | Female patients of childbearing age with SLE | Patients explaining the need for a planned pregnancy |
| QI 1-3 | Female patients of childbearing age with SLE who are aPL negative, have stable or low disease activity, have no desire to have a baby, and wish to use contraception | Patients proposed effective contraceptive methods (e.g. hormonal contraceptives or intrauterine devices) |
| QI 1-4 | Female patients of childbearing age with SLE of moderate-to-severe disease activity, including nephritis | Patients proposed to use progestin-only contraceptive pills or intrauterine device for contraception |
| QI 1-5 | Male patients with SLE who have not started treatment with gonadotoxic drugs and who plan to become pregnant | Patients who proposed cryopreservation of sperm |
| QI 1-6 | Female patients of childbearing age with SLE who are on fertility medications, have stable disease activity, aPL negative, and desire to have a baby | Patient proposed assisted reproductive treatment if necessary |
| QI 1-7 | Female patients with SLE who have stable disease activity and undergo ovarian stimulation | Patients continued on necessary and tolerable immunosuppressive medications |
| QI 1-8 | Obstetric and/or thrombotic APS female patients | Patients who avoided hormone replacement therapy in assisted reproductive medicine |
| QI 1-9 | Female patients with SLE planning pregnancy | Patients in remission for at least 6 months prior to pregnancy |
| QI 1-10 | Female SLE patients with severe pulmonary hypertension* *Estimated systolic PAP >50 mmHg or symptomatic | Patients explained contraception |
| QI 1-11 | Female SLE patients with severe constrictive lung disease* *FVC <50% of predicted value | Patients explained contraception |
| QI 1-12 | Female patients with SLE with severe heart failure* *WHO Class IV including severe ventricular dysfunction with LVEF <30% and NYHA Class III–IV | Patients explained contraception |
| QI 1-13 | Female patients with SLE with severe renal failure* *Serum creatinine ≥ 2.8 mg/dl (500 mmol/l) | Patients explained contraception |
| QI 1-14 | Female patients with SLE who developed thrombosis within 6 months | Patients explained contraception |
| QI 1-15 | Female patients with SLE who had a flare-up of lupus nephritis | Patients explained contraception for 6 months after remission |
| QI 2-1 | Patients with SLE before and during the first trimester of pregnancy | Patients tested for anti-SS-A/Ro and anti-SS-B/La antibodies |
| QI 2-2 | Patients with SLE before pregnancy | Patients tested for aPL |
| QI 2-3 | Patients with SLE planning a pregnancy | Patients with complete blood count and biochemistry, renal function parameters (urinalysis including sediment, urine protein/creatinine ratio), C3, C4, and double-stranded anti-DNA antibodies tested at the stage of planned pregnancy |
| QI 2-4 | Pregnant patients with SLE with lupus nephritis in remission | Patients with serum creatinine and urine protein-creatinine ratios tested at least every 4 weeks |
| QI 2-5 | Pregnant patients with SLE with lupus nephritis | Patients who had blood pressure measurements and urinalysis every 4 weeks until 28 weeks’ gestation, every 2 weeks until 36 weeks, and then weekly thereafter until delivery |
| QI 2-6 | Pregnant patients with SLE positive for anti-SS-A/Ro and/or anti-SS-B/La antibodies | Patients tested for foetal echocardiography |
| QI 3-1 | Patients with SLE starting treatment with drugs that may affect gonadal function | Patients discussing pregnancy planning prior to drug initiation |
| QI 3-2 | Patient with SLE who discontinued teratogenic drugs prior to pregnancy | Patients who have been observed without medication or transitioned to a drug that can be used during pregnancy |
| QI 3-3 | Female patient with SLE planning pregnancy | Patients who discontinued MTX at least 1 month prior to pregnancy |
| QI 3-4 | Female patient with SLE planning pregnancy | Patients who discontinued MMF at least 6 weeks prior to pregnancy |
| QI 3-5 | Female patient with SLE planning pregnancy | Patients who discontinued CYC at least 3 months prior to pregnancy |
| QI 3-6 | Male patients with SLE who wish to become pregnant | Patients who avoided receiving CYC |
| QI 3-7 | Male patients with SLE who are using HCQ and AZP and wish to become pregnant | Patients who continued to use HCQ and AZP |
| QI 3-8 | Pregnant patients with SLE who have been inadvertently exposed to teratogenic agents | Patients referred immediately to a maternal foetal medicine specialist, a pregnancy pharmacotherapy specialist, or a genetics counsellor |
| QI 3-9 | Pregnant SLE patient with APS | Patients treated with low-dose aspirin and heparin |
| QI 3-10 | Pregnant SLE patient with APS | Patients who avoided using DOAC |
| QI 3-11 | Pregnant patients with SLE | Patients who avoided the use of MMF, MTX, and CYC |
| QI 3-12 | Pregnant patients with SLE using HCQ | Patients who continued on HCQ during pregnancy |
| QI 3-13 | Female patients with SLE who is positive for anti-SS-A/Ro antibodies and has a history of congenital heart block in a previous child | Patients using HCQ |
| QI 3-14 | Pregnant patients with SLE | Patients who avoided the use of NSAIDs in the third trimester of pregnancy |
| QI 3-15 | Pregnant patients with SLE | Patients who avoided using ARB |
| QI 3-16 | Pregnant patients with SLE on CyA and TAC | Patients monitored for blood pressure, renal function, and drug concentrations |
| QI 3-17 | Obstetric APS patients | Patients receiving prophylactic anticoagulation therapy during the first 6–12 weeks postpartum |
| QI 3-18 | Patients with SLE who are taking corticosteroids and who are breastfeeding | Patients who continued to breastfeed |
| QI 3-19 | Patients with SLE who are using HCQ, AZP, TAC, or rituximab and who are breastfeeding | Patients who continued to use HCQ, AZP, TAC, or rituximab |
| QI 3-20 | Patient with SLE who is breastfeeding | Patients who avoided using CYC and MMF |
Abbreviations: PAP, pulmonary arterial pressure; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; MTX, methotrexate; MMF, mycophenolate mofetil; CYC, cyclophosphamide; HCQ, hydroxychloroquine; AZP, azathioprine; DOAC, direct oral anticoagulant; NSAIDs, non-steroidal anti-inflammatory drugs; ARB, angiotensin-II receptor blocker; CyA, cyclosporin A; TAC, tacrolimus; WHO, World Health Organization.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
